RAPT Therapeutics — Investor Presentation (September 2022)
29 slides from RAPT Therapeutics's investor presentation, Sep 6, 2022
Slide 1: Transforming the Treatment of Cancer and Inflammation
Transforming the Treatment of Cancer and Inflammation September 2022 Corporate Presentation
Slide 2: Legal Disclaimers
Legal Disclaimers Statements in this Presentation that are not statements of historical fact are forward-looking statements. Such forward-looking statements include, without limitation, statements regarding RAPT Therapeutics, Inc.’s (the “Company,” “we,” or “us”) research and clinical development pl
Slide 3: Oral Drugs Targeting Critical Immune Drivers of Disease
Oral Drugs Targeting Critical Immune Drivers of Disease RPT193 (Inflammation): ï,§ Oral agent targets inflammatory Th2 cellsï,§ Phase 1b in AD: efficacy on all key exploratory endpoints with excellent safety and tolerability ïƒ~ Proprietary discovery engineï,§ Phase 2b in AD ongoing ïƒ~ Diversified
Slide 4: Proprietary Drug Discovery and Development Engine
Proprietary Drug Discovery and Development Engine Rapidï,§ Drug discovery Rï,§ Clinical development to POC Analyticsï,§ Interrogating clinically-relevant big datasets A to identify targets and biomarkers Patient selectionï,§ Driven by data to improve chances P of clinical successï,§ Critical immune
Slide 5: RPT193: CCR4 Antagonist for Inflammatory Diseases
RPT193: CCR4 Antagonist for Inflammatory Diseases
Slide 6: RPT193: Oral CCR4 Antagonist for Inflammatory Diseases
RPT193: Oral CCR4 Antagonist for Inflammatory Diseases ï,§ Highly potent and selective once-daily oral Normal Human Skin AD Lesional Skin CCR4 antagonist designed to safely reduce inflammation in broad range of allergic disordersï,§ Phase 1b trial demonstrated clear benefit in moderate-to-severe AD
Slide 7: RPT193 Targets Th2 Cells: Key Drivers of Inflammation
RPT193 Targets Th2 Cells: Key Drivers of Inflammation in Atopic Dermatitis, Asthma and Other Diseases Allergen, Microbes Epithelial Barrier Surface CCL17 RPT193 is a potent and selective oral CCR4 CCL22 antagonist that specifically inhibits Th2 cell CCR4 migration and activation Signaling via CCR4 r
Slide 8: Atopic Dermatitis and Asthma Represent Major Markets
Atopic Dermatitis and Asthma Represent Major Markets ï,§ Atopic Dermatitis (AD) – Common disease affecting ~19M adults and ~10M children in the US – $24B projected market by 2029* ï,§ Asthma – Asthma affects ~15M adults and children in the US – $21B projected market by 2029* ï,§ High unmet need: a w
Slide 9: Phase 1b Trial Explored RPT193 Activity in Moderate-to-Severe Atopic Dermatitis
Phase 1b Trial Explored RPT193 Activity in Patients with Moderate-to-Severe Atopic Dermatitis Screening Treatment Follow-up (Up to 35 days) (28 days) (14 days) • ≥12-month history of AD (2:1) • 18-65 years of age RPT193 400 mg once daily Obtain (inclusive) Informed • BMI ≥18 and <40 kg/m2 Consent •
Slide 10: Phase 1b Baseline Demographics and Disease Characteristics
Phase 1b Baseline Demographics and Disease Characteristics Placebo RPT193 N 10 21 Age, Mean (Range) 35.8 (22-64) 41.0 (19-63) Female, n (%) 4 (40.0%) 12 (57.1%) Baseline Characteristics EASI, Mean (Range) 21.07 (13.6-45.5) 18.49 (12-30) BSA, Mean (Range) 24.5 (10-61) 23.3 (11-55) vIGA 3, n (%) 8 (80
Slide 11: RPT193 Differentiated from Placebo for EASI and EASI-50 at Day 29
RPT193 Differentiated from Placebo for EASI and EASI-50 at Day 29 with Further Improvement at Day 43 % Improvement in EASI Proportion of EASI-50 60% Treatment Follow-up 70% Treatment Follow-up 50% 60% 50% 40% 40% 41.9%* 30% 43.6%* 19.3% 30% 32.9% 20% 20% 10% 10% 0% 0% Day 1 Day 8 Day 15 Day 29 Day 4
Slide 12: RPT193 Differentiated from Placebo on EASI-75 and vIGA 0/1 at Day 43
RPT193 Differentiated from Placebo on EASI-75, 90 and vIGA 0/1 at Day 43 Proportion of EASI-50, 75, 90 and vIGA 0/1 (Clear/Almost Clear) 70% * 60% 61.9% 50% 40% 30% 28.6% 20% 20% 9.5% 14.3% 10% 0% 0% 0% 0% EASI-50 EASI-75 EASI-90 vIGA 0/1 PbO RPT193 *p < 0.05 12
Slide 13: RPT193 Differentiated from Placebo in Patients with Baseline EASI ≥16
RPT193 Differentiated from Placebo on EASI-75, 90 and vIGA 0/1 at Day 43 in Patients with Baseline EASI ≥16 Proportion of EASI-50, 75, 90 and vIGA 0/1 (Clear/Almost Clear) 70% ** 63.6% 60% 50% 40% 36.4% 30% 27.3% 20% 10% 9.1% 0% 0% 0% 0% 0% EASI-50 EASI-75 EASI-90 vIGA 0/1 PbO RPT193 (N=8) (N=11) **
Slide 14: RPT193 Improved AD-Associated Gene Signatures in the Skin
RPT193 Demonstrated Significant Improvement in AD-Associated Gene Signatures in the Skin RPT193 PB Mean % Improvement in Median % Improvement in MADAD Transcriptome MADAD Transcriptome NL Day1 Day29 NL Day1 Day29 *** 75 *** 52% 50 40 53% 25 ***(p<0.001) 20 12% Improvement Improvement 0 MADAD: Meta-
Slide 15: RPT193 Demonstrated Improvement in Itch and Sleep
RPT193 Demonstrated Improvement in Itch and Sleep Proportion of NRS-4† % Change in Subjective SCORAD (Sleep Loss + Pruritus) 50% 45.0% 80% Day 1 Day 8 Day 15 Day 29 Day 43 40% 60% 40% 30% 20% 22.2% 0% 20% -20% 10% -40% * -60% 0% -80% PbO RPT193 PbO RPT193 †At least a 4-point improvement among patien
Slide 16: RPT193 6-Week Efficacy Compared to Other Drugs at 12-16 Weeks
RPT193 6-Week Efficacy Compared to Other Drugs at 12-16 Weeks* 0 20 40 60 100 % EASI improvement RPT193 EASI-50 RPT193 EASI-75 RPT193 vIGA 0 or 1 All data shown are placebo-adjusted RPT193 RPT193 Dupilumab Lebrikizumab Tralokinumab Abrocitinib Baricitinib Etrasimod Upadicitinib 400 mg Ph3 Ph2 Ph3 Ph
Slide 17: Phase 1b Safety
Phase 1b Safety ï,§ No SAEs reported ï,§ All AEs reported were mild or moderate in intensity ï,§ No clinically significant safety laboratory abnormalities observed ï,§ Overall safety profile to date suggests a well-tolerated oral drug that should not require laboratory safety monitoring 17
Slide 18: Dose Range-Finding Phase 2b Monotherapy Trial in Atopic Dermatitis
Dose Range-Finding Phase 2b Monotherapy Trial in Patients with Moderate-to-Severe Atopic Dermatitis Screening Treatment Follow-up (Up to 5 weeks) (16 weeks) (up to 8 weeks) RPT193 400 mg once daily • ≥12-month history of AD (1:1:1:1) RPT193 200 mg once daily Obtain • 18-75 years of age Informed BMI
Slide 19: Potential "Pipeline in a Product"
Potential “Pipeline in a Product” Dermatology Respiratory Allergy Atopic Dermatitis Asthma Chronic Rhinosinusitis Chronic Urticaria COPD (Th2 high) Allergic Rhinitis Alopecia Areata IPF Eosinophilic Esophagitis Prurigo Nodularis Bullous Pemphigoid Th2-Driven Inflammatory Diseases
Slide 20: RPT193 Program Summary
RPT193 Program Summary ï,§ Data from Phase 1b study in patients with atopic dermatitis demonstrated clear benefit on all key exploratory clinical endpoints, including EASI and vIGAï,§ Continued deepening of responses through 2-week follow-up period suggests higher levels of efficacy could be achieve
Slide 21: FLX475: CCR4 Antagonist for Oncology
FLX475: CCR4 Antagonist for Oncology
Slide 22: Treg Are Key Targets in the Tumor Microenvironment
Treg Are Key Targets in the Tumor Microenvironment (TME) Cancer Types CD8 ï,§ Correlate with poor prognosis across most cancers Tregï,§ Mechanism for immune evasion by viruses and tumorsï,§ Barrier to checkpoint inhibitor efficacyï,§ Challenge: selective inhibition of Treg in the TME – Depleting ant
Slide 23: FLX475: Oral CCR4 Antagonist in Phase 2
FLX475: Oral CCR4 Antagonist in Phase 2 ï,§ Highly potent and selective CCR4 small molecule antagonistï,§ Selectively blocks tumor Treg while sparing normal tissues and beneficial cellsï,§ Potential for superior safety and efficacy compared to depleting antibodiesï,§ Issued U.S. composition of matte
Slide 24: Identification and Characterization of Charged Tumors
Identification and Characterization of Charged Tumors Gastric EBV+ NPC EBV+ “Charged” tumors: high ï,§ levels Cervical HPV+ of CCR4 ligands, Treg and CD8 HNSCC TNBC T cells NSCLC Sq. NHL ï,§ Potential for both monotherapy Treg NSCLC Ad. and combination activityï,§ Represent cancers with high unmet n
Slide 25: Phase 2: Gated Simon 2-Stage Design
Phase 2: Gated Simon 2-Stage Design ï,§ To evaluate the antitumor activity of FLX475 as monotherapy and in combination with pembrolizumab in charged cancers that progressed after ≥ 1 line of therapy FLX475 Monotherapy FLX475 w/ Pembrolizumab + Non-Small Cell Lung Nasopharyngeal (EBV ) (CPI Experienc
Slide 26: Phase 2: Status and Stage Decisions
Phase 2: Status and Stage 2 Decisions Stage 2 Initiated EBV+ Lymphoma Mono and Combo Stage 1 Pending Nasopharyngeal (EBV+) Stage 1 Stage 2 Combination Cervical Monotherapy (CPI Naïve) N=10 N=19 Head & Neck (CPI Naïve) per cohort per cohort Combination Head Combination & Neck (CPI Exp.)
Slide 27: FLX475 Program Summary
FLX475 Program Summary ï,§ FLX475, a highly selective tumor Treg inhibitor, appears to be an active agent in charged cancers as monotherapy and in combination with pembrolizumabï,§ Ungated Stage 2 expansions in 4 indicationsï,§ Favorable safety supportive of broad combinabilityï,§ Targeting a medica
Slide 28: Key Takeaways and Upcoming Milestones
Key Takeaways and Upcoming Milestones ï,§ RPT193: safe oral agent designed for a broad range of inflammatory diseases, in Phase 2b in AD ï,§ FLX475: highly selective tumor Treg inhibitor in multiple Phase 2 expansions as monotherapy and in combination with pembrolizumab ï,§ Planned Key Milestones –
Slide 29: Thank You
8@ Thank You
RAPT Therapeutics — Investor Presentation (September 2022) on 6ix